Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.21M | $-22.39M | $-7.19 |
| 2024 | $5.82M | $-12.98M | $-48.75 |
| 2023 | $4.91M | $-13.32M | $-106000.00 |
| 2022 | $224.0K | $-20.27M | $-288750.00 |
| 2021 | $0.00 | $-13.40M | $-444500.00 |
Social Signal Score
Earnings
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, May 15$-1.05 vs $-0.95miss
- Thu, Mar 12$-0.83 vs $-0.80miss
- Thu, Oct 30$-0.04 vs $-0.02miss
- Thu, Aug 14$-0.01 vs $-0.09beat
- Fri, May 30$-0.56 vs $-0.25miss
- Thu, Mar 27$-0.67 vs $-0.51miss
Estimates and results for PSTV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
PSTVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·2d ago·Negative
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Health Care Service Corporation (“HCSC”), effective August 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumo
View source ↗